The IQGAP2 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma line. This heterogeneous pool carries gene-disrupting edits at the IQGAP2 locus, enabling loss-of-function studies without clonal selection. The polyclonal format maintains genetic diversity while abolishing IQGAP2 expression, suitable for population-level analyses of scaffold protein function in non-small cell lung cancer (NSCLC).
NCI-H1975 parental line is a well-established model of lung adenocarcinoma bearing activating EGFR mutations (L858R/T790M). These mutations drive constitutive signaling through MAPK and PI3K/AKT pathways, conferring oncogene addiction and sensitivity to tyrosine kinase inhibitors. NCI-H1975 cells are extensively used to study EGFR-targeted therapy resistance, epithelial-to-mesenchymal transition, and metastasis, making them a clinically relevant background for tumor suppressor studies.
IQGAP2 is a multi-domain scaffold protein that integrates cell adhesion with actin cytoskeletal dynamics. It directly interacts with F-actin, calmodulin, CDC42, RAC1, E-cadherin, and beta-catenin, linking the cadherin/catenin complex to Arp2/3-mediated actin polymerization. Downstream of EGFR and growth factor signals, IQGAP2 regulates cell?Ccell junction stability and migration. IQGAP2 knockout disrupts E-cadherin?Cbeta-catenin complex integrity and Rho GTPase coordination, leading to cytoskeletal reorganization and potential beta-catenin nuclear translocation, which may modulate Wnt target gene expression.
In the EGFR-mutant lung adenocarcinoma background, IQGAP2 loss helps dissect crosstalk between oncogenic EGFR signaling and cytoskeletal remodeling. As a scaffold restraining cell motility and maintaining adhesion, its knockout is expected to promote a migratory, invasive phenotype, possibly recapitulating aspects of epithelial-to-mesenchymal transition. This model thus enables investigation of how EGFR pathway activity intersects with IQGAP2-dependent tumor suppression and may reveal mechanisms of EGFR inhibitor resistance or metastasis.
Researchers can apply this polyclonal knockout population in western blotting, immunofluorescence of E-cadherin and actin stress fibers, transwell migration/invasion assays, and co-immunoprecipitation to assess beta-catenin/E-cadherin complexes. Phospho-signaling analyses can probe EGFR-MAPK pathway changes. The IQGAP2 Knockout NCI-H1975 Polyclonal Cells are ideal for studying tumor suppression, cell migration, EGFR signaling crosstalk, and drug resistance in lung adenocarcinoma. For further information, contact Ascent Research.
